Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Division of Cancer Biology, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
J Natl Cancer Inst. 2024 Jul 1;116(7):1012-1018. doi: 10.1093/jnci/djae075.
Fusion oncoproteins are associated with childhood cancers and have proven challenging to target, aside from those that include kinases. As part of its efforts for targeting childhood cancers, the National Cancer Institute recently conducted a series on Novel Chemical Approaches for Targeting Fusion Oncoproteins. Key learnings on leading platforms and technologies that can be used to advance the development of molecular therapeutics that target fusion oncoproteins in childhood cancers are described. Recent breakthroughs in medicinal chemistry and chemical biology provide new ground and creative strategies to exploit for the development of targeted agents for improving outcomes against these recalcitrant cancers.
融合致癌蛋白与儿童癌症有关,除了那些包含激酶的融合致癌蛋白外,其他的融合致癌蛋白靶向治疗一直极具挑战。作为其儿童癌症靶向治疗工作的一部分,美国国家癌症研究所最近开展了一系列关于“靶向融合致癌蛋白的新型化学方法”的研究。本文描述了可用于推进儿童癌症融合致癌蛋白的分子治疗开发的主要平台和技术。最近在药物化学和化学生物学方面的突破为开发针对这些难治性癌症的靶向药物提供了新的靶点和创新策略。